Veozah Free Trial Program 10-Day Sample Offer For Menopause Symptom Treatment

Oct. 16, 2025, 1:28 p.m.

Tags: veozah

VEOZAH, a neurokinin 3 (NK3) receptor antagonist, is a prescription medication specifically indicated for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause. The manufacturer offers a free trial voucher program that provides eligible patients with a 10-day supply of the medication at no cost. This program is designed to allow new patients to try VEOZAH before committing to a full prescription, with specific eligibility requirements and limitations that patients and healthcare providers should understand before participation.

About VEOZAH and Its Purpose

VEOZAH (fezolinetant) represents a non-hormonal treatment option for women experiencing moderate to severe vasomotor symptoms associated with menopause. Unlike hormone therapies, VEOZAH works through a different mechanism by blocking neurokinin B (NKB) from binding on KNDy neurons, which helps reduce the heat signals that trigger VMS. This approach offers an alternative for women who may not be candidates for hormone therapy due to contraindications or personal preference.

Clinical studies have demonstrated VEOZAH's effectiveness in reducing both the frequency and severity of moderate to severe VMS. According to research conducted on 1,022 women who received one of two doses of VEOZAH (including 45 mg) in two 12-week, randomized, placebo-controlled, double-blind Phase 3 studies, the medication showed statistically significant improvements compared to placebo at both weeks 4 and 12 of treatment. The North American Menopause Society (formerly NAMS) supports the use of and recommends several non-hormonal therapies for the treatment of VMS, including VEOZAH.

The VEOZAH Free Trial Voucher Program

The VEOZAH voucher program provides healthcare providers with the ability to offer their eligible patients a 10-day free trial of the medication. This trial is intended to help patients determine if VEOZAH is an effective treatment for their menopause symptoms before committing to a full prescription. The program is structured to be accessible through healthcare providers rather than direct patient requests.

How the Voucher Program Works

Healthcare providers can participate in the VEOZAH voucher program by ordering vouchers to distribute to their appropriate patients. The process involves:

Registering to request samples through the VEOZAH healthcare provider portal
Completing a request form with required information
Receiving up to 40 vouchers per month (per prescriber)
Distributing these vouchers to eligible new patients

Once a healthcare provider receives the vouchers, they can provide them to qualifying patients who are starting treatment with VEOZAH. The vouchers typically arrive at the provider's address within 10 business days, provided the quantity requested does not exceed the monthly limit of 40 vouchers per prescriber.

Patient Eligibility for the Free Trial

Not all patients are eligible for the VEOZAH free trial voucher program. The specific eligibility criteria include:

Only new patients may use this voucher
Patients who have previously used VEOZAH are not eligible
Patients who are currently using VEOZAH are not eligible
The patient must have commercial insurance coverage
The program is not valid for patients whose prescription claims are reimbursed by any state or federal government program, including but not limited to:
- Medicaid
- Medicare
- Medigap
- Department of Defense (DoD)
- Veterans Affairs (VA)
- TRICARE
- Puerto Rico Government Insurance
- Any state patient or pharmaceutical assistance program

Additionally, patients who move from commercial insurance to federal or state prescription health insurance will no longer be eligible and must notify the program of any such change. The voucher is also not valid for cash-paying patients.

Important Considerations and Limitations

Before participating in the VEOZAH free trial program, both healthcare providers and patients should be aware of several important considerations and limitations:

Non-Transferable and No Cash Value

The VEOZAH voucher offer is not transferable, meaning it cannot be given to another person. It also has no cash value, meaning it cannot be redeemed for money or exchanged for other products or services.

Cannot Be Combined with Other Offers

The voucher cannot be combined with any other offer, free trial, prescription savings card, or discount. This includes programs offered by third-party payers or pharmacy benefit managers that adjust patient cost-sharing obligations, including arrangements referred to as "accumulator" or "maximizer" programs.

Geographic Restrictions

The voucher program is only valid in the 50 United States, Washington DC, and Puerto Rico. It is void where prohibited by law.

No Purchase Required

The voucher offer is not conditioned on any past, present, or future purchase of VEOZAH. Patients do not need to have purchased the product before or after using the voucher to qualify.

Safety Information

VEOZAH comes with important safety information that patients should be aware of before using the medication. The most significant warning is about the risk of hepatotoxicity (liver damage), which has occurred in the postmarketing setting. VEOZAH is contraindicated in women with certain conditions, though the specific contraindications are not fully detailed in the provided source materials.

Patients should discuss their complete medical history, including any liver conditions, with their healthcare provider before starting VEOZAH. Regular monitoring of liver function may be required during treatment.

How Healthcare Providers Can Participate

Healthcare providers interested in offering the VEOZAH free trial to their patients can participate by following these steps:

Access the VEOZAH healthcare provider portal through the official website
Register as a healthcare provider if not already registered
Complete the voucher order form with all required information (fields marked with *)
Request up to 40 vouchers per month for distribution to eligible patients
Distribute vouchers only to qualifying new patients who meet all eligibility criteria
Ensure patients understand the terms and conditions of the voucher program

The form requires completion of all fields marked with asterisks (*), and providers can expect to receive their vouchers at the address provided within 10 business days, provided the quantity requested does not exceed the monthly limit.

Patient Experience with the Free Trial

For patients who receive a VEOZAH voucher, the experience typically involves:

Receiving the voucher from their healthcare provider
Presenting the voucher at their pharmacy when filling their VEOZAH prescription
Receiving a 10-day supply of VEOZAH at no cost (subject to insurance verification)
Using the medication as directed by their healthcare provider
Determining if VEOZAH effectively manages their menopause symptoms
Discussing with their healthcare provider whether to continue treatment with a full prescription

The voucher covers a 10-day VEOZAH prescription, allowing patients sufficient time to evaluate how well the medication works for their individual symptoms before committing to long-term treatment.

Clinical Evidence Supporting VEOZAH

The effectiveness of VEOZAH for treating moderate to severe vasomotor symptoms is supported by clinical research. In two 12-week, randomized, placebo-controlled, double-blind Phase 3 studies involving 1,022 women who received one of two doses of VEOZAH (including 45 mg), the medication demonstrated statistically significant reductions from baseline in the frequency and severity of moderate to severe VMS over 24 hours compared to placebo, both at weeks 4 and 12 of treatment.

After the initial 12-week period in these trials, women who had been receiving placebo were rerandomized to VEOZAH for a 40-week extension to evaluate safety for up to 52 weeks of total exposure. This extended follow-up period provides additional information about the long-term use of VEOZAH.

The North American Menopause Society (formerly NAMS) recognizes VEOZAH as a non-hormonal therapy option for VMS. The organization maintains that hormone therapy (HT) is the most effective treatment for VMS, but acknowledges that not all women are candidates for HT due to contraindications or personal preference, making alternative treatments like VEOZAH valuable options.

Conclusion

The VEOZAH free trial voucher program offers eligible patients an opportunity to try this non-hormonal treatment for moderate to severe vasomotor symptoms associated with menopause at no cost for a 10-day period. The program is accessible through healthcare providers who can order up to 40 vouchers monthly for distribution to qualifying new patients.

Eligibility for the program is limited to patients with commercial insurance who have not previously used or are not currently using VEOZAH. The voucher cannot be transferred, combined with other offers, or used by patients covered by government insurance programs or those paying cash.

While the free trial provides an opportunity for patients to evaluate VEOZAH's effectiveness for their individual symptoms, it's important to consider the medication's safety profile, including the risk of hepatotoxicity, and to discuss all medical conditions with a healthcare provider before starting treatment.

The clinical evidence supporting VEOZAH's effectiveness in reducing vasomotor symptoms, combined with the availability of a free trial option, makes this program a potentially valuable resource for women seeking non-hormonal treatment options for menopause symptoms.